Matthew Biever, DO
Psychiatry · Lancaster, PANPI 1023227741
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $49,885 of the $73,720 with a category attached, or 67.7%. 31 manufacturers reported payments, led by AbbVie at 53.2% of the total. Reporting peaked in 2023 at $27,281 and has fallen 55.3% since, to $12,206 in 2025. Among psychiatry clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 546 payments — averaging $135.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$39K
- Axsome Therapeutics, Inc.$20K
- Otsuka America Pharmaceutical, Inc.$8K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Teva Pharmaceuticals USA, Inc.$863
- Neurocrine Biosciences, Inc.$784
- plus $3K from 25 others
What the payments were for
- Consulting fees$14,60020%
- Speaking & faculty fees$49,88568%
- Food & beverage$8,95312%
- Education$2820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 140 | $39,233 |
| Axsome Therapeutics, Inc. | 26 | $19,997 |
| Otsuka America Pharmaceutical, Inc. | 54 | $8,300 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 66 | $1,438 |
| Teva Pharmaceuticals USA, Inc. | 44 | $863 |
| Neurocrine Biosciences, Inc. | 47 | $784 |
| Johnson & Johnson | 52 | $783 |
| Alkermes, Inc. | 36 | $738 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $334 |
| Lundbeck LLC | 14 | $247 |
| Vanda Pharmaceuticals Inc. | 8 | $227 |
| Ironshore Pharmaceuticals Inc. | 7 | $155 |
| Supernus Pharmaceuticals, Inc. | 6 | $83 |
| Corium, LLC | 4 | $79 |
| Sunovion Pharmaceuticals Inc. | 7 | $66 |
| E.r. Squibb & Sons, L.L.C. | 3 | $58 |
| Indivior Inc. | 3 | $47 |
| Noven Pharmaceuticals, Inc. | 1 | $28 |
| Almatica Pharma LLC | 1 | $27 |
| Adlon Therapeutics L.p. | 1 | $25 |
| Noven Therapeutics, LLC | 1 | $24 |
| Sage Therapeutics, LLC | 1 | $22 |
| Vertical Pharmaceuticals, LLC | 1 | $22 |
| Neuronetics, Inc. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
| Neos Therapeutics, LP | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Tris Pharma Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$37,600
- Auvelity$19,727
- ABILIFY MAINTENA$7,610
- ABILIFY ASIMTUFII$1,867
- INGREZZA$208
How this compares
$73,720 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 65 | $643,929 |
| Invega SustennaPaliperidone Palmitate | 156 | $540,220 |
| Abilify MaintenaAripiprazole | 78 | $233,613 |
| IngrezzaValbenazine Tosylate | 18 | $151,446 |
| VraylarCariprazine Hcl | 101 | $146,681 |
| RexultiBrexpiprazole | 47 | $84,136 |
| CaplytaLumateperone Tosylate | 49 | $82,875 |
| Tetrabenazine | 31 | $70,237 |
| AristadaAripiprazole Lauroxil | 20 | $61,207 |
| NuedextaDextromethorphan Hbr/Quinidine | 27 | $46,993 |
| Risperdal ConstaRisperidone Microspheres | 26 | $33,038 |
| Lupron DepotLeuprolide Acetate | 13 | $27,063 |
| TrintellixVortioxetine Hydrobromide | 57 | $26,377 |
| LybalviOlanzapine/Samidorphan Malate | 16 | $23,049 |
| Clozapine | 266 | $22,046 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $863 | $643,92965 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $783 | $573,259182 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $8,300 | $317,749125 claims |
| AbbVieVraylar, Lupron Depot | $39,233 | $173,744114 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $784 | $151,44618 claims |
| Alkermes, Inc.Aristada, Lybalvi | $738 | $84,25636 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,438 | $82,87549 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $20 | $46,99327 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $334 | $31,35870 claims |
| Almatica Pharma LLCSertraline Hcl | $27 | $2,681180 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in Lancaster
- Rebecca RomaPittsburgh$3.3M
- Robert NelsonWyomissing$2.2M
- Matthew BergerMoosic$1.7M
- Mark MattaNew Castle$847K
- Mayer AyyashPittsburgh$714K
- Daniel WeintraubPhiladelphia$647K
- Sachin MehtaBlue Bell$646K
- Jane JesseKingston$617K
- Michael ThasePhiladelphia$396K
- Michael KwiatBeaver$390K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.